CTLA4 and neoplasm: The mechanism underlying the clinical activity of CTLA-4 immunotherapy is currently under investigation, and recent experimental findings indicate that antibody-mediated depletion of regulatory T cells (Tregs) in the tumor microenvironment plays a key role in efficacious antitumor responses [78–80].